Latest:
Paving the Way to Modern Cancer Therapy
When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Hans Hammers, MD, PhD
Hans Hammers, MD, PhD, is a professor in the Department of Internal Medicine, a member of the Division of Hematology and Oncology, coleader of Clinical Research and Immunotherapy for the Kidney Cancer Research Program, and the Eugene P. Frenkel, MD Scholar in Clinical Medicine at the University of Texas Southwestern Medical Center
Latest:
Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC
Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.
Hans J. Hammers, MD, PhD, UT Southwestern Medical Center
Latest:
Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence
Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.
Hans-Joachim Schmoll, MD
Latest:
Dr. Schmoll on the Toxicity of the CHARTA Study in CRC
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).
Harry Erba, MD, PhD
Harry P. Erba, MD, PhD, is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute
Latest:
Dr Erba on the FDA Approval of Ziftomenib in NMP1-Mutant Relapsed/Refractory AML
Harry Erba, MD, PhD, discusses the significance of the FDA approval of ziftomenib in NMP1-mutant, relapsed/refractory acute myeloid leukemia.